KRAS and lung adenocarcinoma: At this concept, a study evaluated KRAS mutations in minor clones in patients with lung adenocarcinoma treated with EGFR-TKI, concluding that KRAS mutations might hinder the effectiveness of anti-EGFR therapy [37].